Back to search
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Eva…
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM…
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and…
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.